Xiaodong Guan

Professor, PhD Supervisor

Research Interests: rational use of medicines, equitable access to medicines

Tel: +86-010-82801701

Email:guanxiaodong@pku.edu.cn

EDUCATION

Doctor of Philosophy, Peking University (2011)

Master of Science, Peking University (2008)

Bachelor of Science, Peking University (2004)

ACADEMIC APPOINTMENTS

2017 - present    Peking University, School of Pharmaceutical Sciences

• General Secretary of the Student Communist Party of China Branch (2017-2018)
• Committee Member of the Communist Party of China (2022)
• Assistant to the Dean (2023)

2011 - present    Peking University, School of Pharmaceutical Sciences, Department of Pharmacy Administration and Clinical Pharmacy

• Lecturer (2011), Associate Professor (2018), Master Supervisor (2018), Associate Department Director (2018), Department Director (2019), PhD Supervisor (2020), Principal Investigator (2020), Professor(2023)

2018.9 – 2019.9   Harvard Medical School 

• Visiting Scholar

2004.8 – 2005.7   Datong County, Xining City, Qinghai Province, Ethnicity Complete Middle School

• Volunteer Teacher

PROFESSIONAL AFFILIATIONS

World Health Organization Technical Advisory Group on Pricing Policies for Medicines (WHO TAG-PPM), Expert

China International Exchange and Promotive Association for Medical and Health Care, Member of the Standing Committee, General Secretary (2023)

Key Laboratory of Pharmacovigilance Research and Evaluation, Center for Drug Reevaluation, National Medical Products Administration, Member of the Academic Committee (2021)

Pharmacy Administration Sub-Committee, Modern Hospital Management Capacity Building Expert Committee, National Health Commission Capacity Building and Continuing Education Center, Member (2020) 

AWARDS AND CERTIFICATES

Peking University Model Course on Curriculum Ideology and Politics (2022)

Second Prize of Peking University Teaching Achievements (2022)

Second Prize of Beijing Science and Technology Progress Award (2021)

Title of "My Favorite Mentor", Peking University School of Pharmaceutical Sciences (2020)

Spotlight Poster, 37th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (2020)

John Snow Award, 2018 Annual Meeting of International Society for Pharmacoepidemiology (2018)

Teaching Excellence Award, Peking University Health Science Center (2017, 2018)

Outstanding Communist Party Member, Outstanding Class Teacher Pacesetter, Peking University (2016)

Outstanding Teacher, Peking University Health Science Center (2013, 2015)

REPRESENTATIVE PUBLICATIONS (2022-2023)

1.Hu L, Fu M, Wushouer H, Ling K, Shi L, Guan X*. Association Between β-lactam Allergy Documentation and Outpatient Antibiotic Prescribing in Primary Healthcare Facilities in China.J Hosp Infect. 2023 Sep 1:S0195-6701(23)00282-7.(SCIE, Q1, IF-2022=6.9)

2.Fu M, Gong Z, Li C, Ling K, Zhu Y, Li H, Shi L, Guan X*. Appropriate use of antibiotics for acute respiratory infections at primary healthcare facilities in China: a nationwide cross-sectional study from 2017 to 2019.Lancet Reg Health West Pac. 2023 Aug 18;40:100880.(SCIE, SSCI, Q1, IF-2022=7.1)

3.Yang Y, Zhang Y, Wagner AK, Li H, Shi L, Guan X*. The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data.J Glob Health. 2023 Aug 11;13:04083.(SCIE, SSCI, Q1, IF-2022=7.2)

4.Bai L, Zhan Y, Zhou Y, Zhang Y, Shi L, Gupta S, Denburg A, Guan X*. Evidence of clinical benefit of WHO essential anticancer medicines for children, 2011-2021. EClinicalMedicine. 2023 Apr 12;59:101966. (SCIE, Q1, IF-2022=15.1)

5.Wushouer H, Zhou Y, Zhang W, Hu L, Du K, Yang Y, Yao G, Little P, Zheng B, Guan X*, Shi L. Inpatient antibacterial use trends and patterns, China, 2013-2021.Bull World Health Organ. 2023 Apr 1;101(4):248-261B. (SCIE, Q1, IF-2022=11.1)

6.Zhang Y, Wagner AK, Guan X*. Newly approved cancer drugs in China - innovation and clinical benefit.Nat Rev Clin Oncol. 2023 Mar;20(3):135-136. (SCIE, Q1, IF-2022=78.8)

7.Fu M, Zhu Y, Gong Z, Li C, Li H, Shi L*, Guan X*. Benzodiazepine Receptor Agonists Prescribing for Insomnia Among Adults in Primary Health Care Facilities in Beijing, China. JAMA Netw Open.2023 Feb 1;6(2):e230044. (SCIE, Q1, IF-2022=13.8)

8.Wushouer H, Yang Y, Deng Y, Zheng B, Shi L, Guan X*. A comparative study of antibiotic use in China under Chinese restriction list and world health Organization AWaRe classification.Clin Microbiol Infect. 2022 Dec 13:S1198-743X(22)00631-0. (SCIE, Q1, IF-2022=14.2)

9.Fu M, Gong Z, Zhu Y, Li C, Zhou Y, Hu L, Li H, Wushouer H, Guan X*, Shi L. Inappropriate antibiotic prescribing in primary healthcare facilities in China: a nationwide survey, 2017-2019.Clin Microbiol Infect. 2022 Nov 25:S1198-743X(22)00587-0. (SCIE, Q1, IF-2022=14.2)

10.Zhang Y, Naci H, Wagner AK, Xu Z, Yang Y, Zhu J, Ji J, Shi L, Guan X*. Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020. JAMA Netw Open.2022;5(8):e2225973. (SCIE, Q1, IF-2022=13.8)

11.Zhang Y, Guan X. Misleading Reporting in Statistically Not Significant Oncology Trials-Joining Efforts Toward Unbiased Results Interpretation. JAMA Netw Open.2021 Dec 1;4(12):e2138695. (SCIE, Q1, IF-2021=13.36)

12.Naci H, Guan X, Woloshin S, Xu Z, Wagner AK. Communication of Survival Data in US Food and Drug Administration-Approved Labeling of Cancer Drugs. JAMA Intern Med.2021 Nov 1;181(11):1521-1522. (SCIE, Q1, IF-2021=44.424)

13.Fu M, Naci H, Booth C, Gyawali B, Cosgrove A, Toh S, Xu Z, Guan X, Ross-Degnan D, Wagner A. Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018.JAMA Intern Med. 2021 Oct 18;e215983. (SCIE, Q1, IF-2021=44.424)

14.Huang T, Wagner A, Bai L, Huang C, Guan X*, Shi L. Anticancer medicines in China: Trends in daily therapy cost and relative procurement volume and spending. Cancer Commun (Lond).2021 Apr;41(4):345-348.(SCIE, Q1, IF-2021=15.283)

15.He Z, Huang X, Chen D, Wang G, Zhu Y, Han S, Guan X*, Shi L. The pharmacoeconomic analyses of the Chinese national drug negotiations: a systematic review.Chinese Journal of Evidence-Based Medicine.2023,23(02):159-169.

16.Yang Y, Hu H, Huang T, Gong Z, Guan X*, Shi L. Use of patient-sharing techniques to study healthcare provider networks: a scoping review. Chinese Journal of Evidence-Based Medicine.2023,23(02):197-202.

17.Bao Q, Hu L, Hu H, Huang T, Fu M,Wushouer H, Guan X*, Shi L. Correlation analysis between the judgment of medical damage liability disputes related to off-label drug use and evidence-based evidence. China Pharmacy.2022,33(15):1810-1813+1819.